Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
full-year 2026 net product revenue guidance of US$480 million to US$495 million. The company also filed an sNDA to extend ZORYVE cream 0.05% to infants as young as 3 months with mild to moderate atopic dermatitis, potentially widening its addressable pediatric market with a steroid-free option in a segment that currently has only one other approved non-steroidal choice. Now we'll examine how this combination of stronger quarterly results and reaffirmed revenue guidance may influence Arcutis's existing investment narrative. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 33 companies in the world exploring or producing it . Find the list for free. Arcutis Biotherapeutics Investment Narrative Recap To own Arcutis, you need to believe that the ZORYVE franchise can support a sustainable, eventually profitable dermatology business despite its concentration risk. The stronger first quarter and reaffirmed 2026 revenue outlook support the near te
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical DermatologyGlobeNewswire
- Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswire
- Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound [Seeking Alpha]Seeking Alpha
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
ARQT
Earnings
- 5/6/26 - Miss
ARQT
Sec Filings
- 5/13/26 - Form 4
- 5/13/26 - Form 4
- 5/12/26 - Form SCHEDULE
- ARQT's page on the SEC website